Europe Drug Regulator Expands GSK's Jemperli/Chemo Combo To …
4 days ago · On Monday, the European Commission approved GSK plc’s (NYSE:GSK) Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line …
GSK CEO Optimistic About Dealmaking, Trump Administration
GSK Plc’s Chief Executive Officer Emma Walmsley is looking to do more deals as the British drugmaker doubles down on its return to cancer medicines.
Next stage in GSK’s Zantac defense gets underway today
3 days ago · GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused …
JPM25: GSK's CSO shares science strategy behind deal-heavy year
Jan 15, 2025 · Following GSK’s deal-heavy end to 2024, Chief Scientific Officer Tony Wood, Ph.D., doesn’t expect the trend to let up in the new year, zeroing in on partnerships that can …
GSK enters agreement to acquire IDRx, Inc. | GSK
Jan 13, 2025 · GSK to pay up to $1.15 billion GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire …
GSK to Buy US Biotech Firm IDRx for up to $1.15 Billion - U.S. News
Jan 13, 2025 · (Reuters) -British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a …
FDA fast-tracks GSK’s chronic hep B therapy bepirovirsen
3 days ago · GSK’s antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, will get a rapid six-month review from the FDA when it is filed for approval, said the drugmaker this …
GSK plc (GSK) Stock Price, News, Quote & History - Yahoo Finance
Find the latest GSK plc (GSK) stock quote, history, news and other vital information to help you with your stock trading and investing.
GSK to Pay Over $2 Billion in Bid to End Most U.S. Zantac Lawsuits ...
Oct 9, 2024 · GSK agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its discontinued heartburn medicine Zantac causes cancer.
GSK, Merck and Pfizer in Ab&B’s sights as biotech files for IPO
2 days ago · Ab&B filed for an IPO to fund development of vaccines that could compete with shots from companies including GSK, Merck & Co. and Pfizer.